You are using a browser that is not supported by this site. The site will not function properly. Please switch to the latest version of a supported browser such as Chrome, Safari, Edge, or Firefox to use this site.
United Therapeutics—Our Story
Remodulin is produced by United Therapeutics Corporation, a biotechnology company founded by Martine and Bina Rothblatt in 1996, after their daughter was diagnosed with PAH.
United Therapeutics was born from a very personal and passionate desire to develop medicines that could help people with PAH, like you, who are suffering from this rare disease. We've recently taken that commitment a step further by becoming the first public pharmaceutical company to convert to a public benefit corporation (PBC), which legally requires us to consider the best interests of everyone involved with United Therapeutics—especially patients.
You can read more about what it means to be a PBC here.
We are committed to helping people affected by PAH.
A personal note from our founder
When our daughter was diagnosed with pulmonary arterial hypertension (PAH), almost no treatment options were available. That’s why we decided to form United Therapeutics (UT) and dedicate ourselves to creating treatments for PAH.
Soon after we started that journey, our family spoke with others in similar situations and found there were limited support options available for people impacted by PAH. That’s when we realized UT could be doing more than creating new treatments.
We want to empower people throughout their PAH journeys—which is why support is such an integral part of our treatments. We are committed to helping people affected by PAH, until there is a cure.
Martine Rothblatt, PhD
Chairman and CEO
United Therapeutics Corporation
Remodulin® (treprostinil) Injection
Important Safety Information for Remodulin
Before you take Remodulin, tell your healthcare provider if you:
- Have other medical conditions or take other medicines that may affect your use of Remodulin by increasing the risk of side effects or decreasing the drug’s effectiveness.
- Have liver or kidney problems. Your Remodulin dose may need to be adjusted if you have liver problems.
- Have low blood pressure or bleeding problems.
- Are taking gemfibrozil (for high cholesterol), rifampin (for infection) or other drugs that affect liver enzymes. Your doctor may need to adjust your Remodulin dosage.
- Are pregnant, breastfeeding, or planning to become pregnant. It is not known if Remodulin will harm your unborn baby or if Remodulin passes into your breast milk.
What are the serious side effects of Remodulin?
- Continuous intravenous (IV) infusions of Remodulin delivered using an external infusion pump, with a tube placed in a central vein within the chest, are associated with the risk of blood stream infections and sepsis, which may be fatal. Therefore, continuous subcutaneous (SC) infusion delivered just beneath the skin is the preferred type of delivery.
- Worsening of PAH symptoms. Do not stop taking or greatly reduce your Remodulin dose without consulting your doctor.
- Low blood pressure (symptomatic hypotension). If you have low blood pressure or are taking drugs that lower your blood pressure, the risk of low blood pressure is increased.
- Bleeding problems. Remodulin may increase the risk of bleeding in people who take blood thinners (anticoagulants).
What are the possible side effects of Remodulin?
- In clinical studies of SC infusion of Remodulin, most people experienced infusion site pain and infusion site reaction (redness, swelling, and rash). These symptoms were sometimes severe and sometimes required treatment with narcotics or discontinuation of Remodulin.
- IV infusion of Remodulin delivered through an external pump has been associated with the risk of blood stream infections, arm swelling, tingling sensations, bruising, and pain.
- The most common side effects seen with either SC or IV Remodulin were headache, diarrhea, nausea, rash, jaw pain, widening of the blood vessels (vasodilatation), and swelling from fluid retention (edema). These are not all the possible side effects of Remodulin. Call your doctor for medical advice about side effects.
You may report side effects to the FDA at www.fda.gov/MedWatch or call 1-800-FDA-1088.
You may report side effects to the FDA at www.fda.gov/MedWatch or call 1-800-FDA-1088.
The risk information provided here is not comprehensive.
What is Remodulin?
Remodulin is a prescription medication used to treat adults with pulmonary arterial hypertension (PAH; WHO Group 1), which is high blood pressure in the arteries of your lungs. Remodulin can reduce symptoms associated with exercise. Remodulin was studied mainly in patients with NYHA Functional Class II-IV symptoms. It is not known if Remodulin is safe and effective in children.
In people with PAH who need to switch from epoprostenol, Remodulin is approved to slow the worsening of symptoms.
REMISIconMAY2021
To learn more about Remodulin, talk with your healthcare provider. Please see Full Prescribing Information at www.remodulin.com or call Customer Service at 1-877-UNITHER (1-877-864-8437).
To learn more about Remodulin, talk with your healthcare provider. Please see Full Prescribing Information at www.remodulin.com or call Customer Service at 1-877-UNITHER (1-877-864-8437).
PAH=pulmonary arterial hypertension; WHO=World Health Organization.
Remodulin® (treprostinil) Injection
Important Safety Information for Remodulin
Before you take Remodulin, tell your healthcare provider if you:
- Have other medical conditions or take other medicines that may affect your use of Remodulin by increasing the risk of side effects or decreasing the drug’s effectiveness.
- Have liver or kidney problems. Your Remodulin dose may need to be adjusted if you have liver problems.
- Have low blood pressure or bleeding problems.
- Are taking gemfibrozil (for high cholesterol), rifampin (for infection) or other drugs that affect liver enzymes. Your doctor may need to adjust your Remodulin dosage.
- Are pregnant, breastfeeding, or planning to become pregnant. It is not known if Remodulin will harm your unborn baby or if Remodulin passes into your breast milk.
What are the serious side effects of Remodulin?
- Continuous intravenous (IV) infusions of Remodulin delivered using an external infusion pump, with a tube placed in a central vein within the chest, are associated with the risk of blood stream infections and sepsis, which may be fatal. Therefore, continuous subcutaneous (SC) infusion delivered just beneath the skin is the preferred type of delivery.
- Worsening of PAH symptoms. Do not stop taking or greatly reduce your Remodulin dose without consulting your doctor.
- Low blood pressure (symptomatic hypotension). If you have low blood pressure or are taking drugs that lower your blood pressure, the risk of low blood pressure is increased.
- Bleeding problems. Remodulin may increase the risk of bleeding in people who take blood thinners (anticoagulants).
What are the possible side effects of Remodulin?
- In clinical studies of SC infusion of Remodulin, most people experienced infusion site pain and infusion site reaction (redness, swelling, and rash). These symptoms were sometimes severe and sometimes required treatment with narcotics or discontinuation of Remodulin.
- IV infusion of Remodulin delivered through an external pump has been associated with the risk of blood stream infections, arm swelling, tingling sensations, bruising, and pain.
- The most common side effects seen with either SC or IV Remodulin were headache, diarrhea, nausea, rash, jaw pain, widening of the blood vessels (vasodilatation), and swelling from fluid retention (edema). These are not all the possible side effects of Remodulin. Call your doctor for medical advice about side effects.
You may report side effects to the FDA at www.fda.gov/MedWatch or call 1-800-FDA-1088.
The risk information provided here is not comprehensive.
What is Remodulin?
Remodulin is a prescription medication used to treat adults with pulmonary arterial hypertension (PAH; WHO Group 1), which is high blood pressure in the arteries of your lungs. Remodulin can reduce symptoms associated with exercise. Remodulin was studied mainly in patients with NYHA Functional Class II-IV symptoms. It is not known if Remodulin is safe and effective in children.
In people with PAH who need to switch from epoprostenol, Remodulin is approved to slow the worsening of symptoms.
REMISIconMAY2021
To learn more about Remodulin, talk with your healthcare provider. Please see Full Prescribing Information at www.remodulin.com or call Customer Service at 1-877-UNITHER (1-877-864-8437).
PAH=pulmonary arterial hypertension; WHO=World Health Organization.